Lung cancer adjuvant therapy

Belani CP. Adjuvant and neoadjuvant therapy in non-small cell lung cancer. Semin Oncol 2005 32(2 suppl 2) S9-15. 

Takeda et al. (64) performed a phase I/II study consisting of low-dose CDDP (6-10 mg/m2/d) and UFT (600 mg/d) combined with radiotherapy (50 Gy/25 fractions) as postoperative adjuvant therapy following curative resection for patients with nonsmallcell lung cancer (NSCLC). The combined therapy was well tolerated and resulted in a disease-free survival rate of 78% at 2 yr. Another study in a small number of patients with unresectable stage III nonsmall-cell lung cancer, UFT (400 mg/m2 on d 1-52) and CDDP (80 mg/m2 on d 8,29, and 50) were administered with radiation therapy (total dose of 60.8 Gy in 38 fractions on d 1-52). Among 17 evaluable patients, 94% (16 patients) achieved partial responses with median time to tumor progression of 30 wk, and the... 

The Ludwig Lung Cancer Study Group (LLCSG). Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. Cancer 1986 58(ll) 2411-6. 

Ludwig Lung Cancer Study Group. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1985 89(6) 842-7. 

Several clinical trials of isotretinoin have been initiated. Ongoing studies in advanced cancers include chronic myelogenous leukemia, carcinoma of the head and neck, and myelodysplastic syndromes. Adjuvant therapy trials are ongoing in non-small cell lung cancer, head and neck carcinoma, and malignant melanoma. Most of these trials utilize a randomized double-blind design. Unfortunately, for most of these studies (especially the adjuvant trials) definitive results will not be available for several years. 

Sawyer TE, Bonner JA, Gould PM, et al. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall-cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 1997 80 1399-1408. 

---